We believe that endothelial cell CTGF-dependent interaction with Cdc42 in the recruitment of circulating CD11b+ myeloid cells is a singular example of a relevant protective pathway, possibly contributing to observed benefit in human clinical trials of anti-CTGF drugs related to pulmonary disease. The gene discussed is CCN2; the disease is lung disorder.